ArticleMalaria journal2025
Patterns of patent and sub-patent Plasmodium falciparum infections in household members of children under seasonal malaria chemoprevention coverage in the health district of Nanoro, Burkina Faso.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundSeasonal Malaria Chemoprevention (SMC) has been adopted since 2014 in Burkina Faso to reduce malaria burden in children under 5 years. However, the intervention's expected potential has not yet been achieved in real-life conditions, suggesting other factors may influence its effectiveness. Asymptomatic carriers, including patent and sub-patent Plasmodium falciparum infections in household members seems to be a potential factor maintaining the high malaria burden in children under SMC coverage. This study assessed the patterns of these infections in household members living around children under SMC coverage in Nanoro, Burkina Faso.
methodsA cross-sectional survey nested to a large SMC study named "SMC_RST" was conducted during the 2022 SMC campaign in Nanoro, including 745 participants. Sub-patent infections were defined as varATS qPCR-positive/RDT-negative, and patent infections as positive by both methods. Prevalence of patent and sub-patent malaria infections were presented with 95% confidence intervals (CI), accounting for clustering of individuals within households. Multinomial regression with robust standard errors assessed the effect of age, sex, and locations on risk of malaria infection.
resultsOut of 745 participants, diagnostic results regarding malaria status were available for 650 (87.2%). Plasmodium falciparum infections in household members were detected in 68.6% (446/650, 95% CI: 64.7-72.5), including 27.4% (178/650, 95% CI: 23.9-30.8) patent and 41.2% (268/650, 95% CI: 37.3-45.2) sub-patent infections. Patent infections declined with age: 37.7%, (95% CI: 31.9-43.5) among 5-14 years, 25% (95% CI: 17.0-33.0) among 15-24 years, and 17.1% (95% CI: 12.6-21.5) among ≥ 25 years. Prevalence of sub-patent infection was 38.0% (95% CI: 32.4-43.7) among 5-14 years, 49.2% (95% CI:40.3-58.1) among 15-24 years and 40.7% (95% CI: 34.5-46.8) among ≥ 25 years. No significant difference across villages was observed in terms of prevalence of household members with patent (χ
conclusionOver two-thirds of the household members living with children under SMC coverage area in Nanoro, Burkina Faso, harboured patent and sub-patent P. falciparum infection. Among those aged 15 years and older, asymptomatic carriage was largely sub-patent. This study supports the extension of the SMC intervention to school-aged children and the implementation of interventions such as testing and treatment of household members of children under SMC coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.